{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:28Z","timestamp":1790957908225,"version":"4.1.0"},"reference-count":161,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"Programa de becas Gilead a la investigaci\u00f3n Biom\u00e9dica","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"Fondo Europeo para el Desarrollo Regional","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]},{"name":"the SPANISH AIDS Research Network","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"the SPANISH AIDS Research Network","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"the SPANISH AIDS Research Network","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"the SPANISH AIDS Research Network","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"the SPANISH AIDS Research Network","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"the SPANISH AIDS Research Network","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"the SPANISH AIDS Research Network","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"the SPANISH AIDS Research Network","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"HIVACAT Programme and the CERCA Programme\/\u201cGeneralitat de Catalunya\u201d","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"\u201cla Caixa\u201d Foundation under agreement","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["GLD21_00111"],"award-info":[{"award-number":["GLD21_00111"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["RD12\/0017\/0001"],"award-info":[{"award-number":["RD12\/0017\/0001"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["RD16\/0025\/0002"],"award-info":[{"award-number":["RD16\/0025\/0002"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"],"award-info":[{"award-number":["RD16\/0025\/0014-ISCIII-FEDER (RIS)"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["PI04\/0363"],"award-info":[{"award-number":["PI04\/0363"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["PI20\/00676"],"award-info":[{"award-number":["PI20\/00676"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["SGR 615"],"award-info":[{"award-number":["SGR 615"]}]},{"name":"CIBERINFEC from the \u201cInstituto de Salud Carlos III\u201d, Madrid, Spain","award":["SGR 653"],"award-info":[{"award-number":["SGR 653"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) have been extensively used as a treatment for chronic myeloid leukemia (CML). Dasatinib is a broad-spectrum TKI with off-target effects that give it an immunomodulatory capacity resulting in increased innate immune responses against cancerous cells and viral infected cells. Several studies reported that dasatinib expanded memory-like natural killer (NK) cells and \u03b3\u03b4 T cells that have been related with increased control of CML after treatment withdrawal. In the HIV infection setting, these innate cells are associated with virus control and protection, suggesting that dasatinib could have a potential role in improving both the CML and HIV outcomes. Moreover, dasatinib could also directly induce apoptosis of senescence cells, being a new potential senolytic drug. Here, we review in depth the current knowledge of virological and immunogenetic factors associated with the development of powerful cytotoxic responses associated with this drug. Besides, we will discuss the potential therapeutic role against CML, HIV infection and aging.<\/jats:p>","DOI":"10.3390\/pharmaceutics15030917","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T06:52:13Z","timestamp":1678690333000},"page":"917","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging"],"prefix":"10.3390","volume":"15","author":[{"given":"Andrea","family":"Rodr\u00edguez-Agust\u00edn","sequence":"first","affiliation":[{"name":"HIV Unit, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Casanova","sequence":"additional","affiliation":[{"name":"HIV Unit, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9350-2429","authenticated-orcid":false,"given":"Judith","family":"Grau-Exp\u00f3sito","sequence":"additional","affiliation":[{"name":"HIV Unit, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonsoles","family":"S\u00e1nchez-Palomino","sequence":"additional","affiliation":[{"name":"HIV Unit, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain"},{"name":"CIBER of Infectious Diseases (CIBERINFEC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-7377","authenticated-orcid":false,"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[{"name":"CIBER of Infectious Diseases (CIBERINFEC), 28029 Madrid, Spain"},{"name":"AIDS Immunopathogenesis Unit, Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-656X","authenticated-orcid":false,"given":"N\u00faria","family":"Climent","sequence":"additional","affiliation":[{"name":"HIV Unit, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain"},{"name":"CIBER of Infectious Diseases (CIBERINFEC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1188\/13.CJON.E13-E20","article-title":"Treating Chronic Myeloid Leukemia: Improving Management through Understanding of the Patient Experience","volume":"17","author":"Simoneau","year":"2013","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_2","first-page":"535","article-title":"Chronic Myelogenous Leukemia","volume":"9","year":"2007","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and Beyond--Exploring the Full Potential of Targeted Therapy for CML","volume":"6","author":"Kantarjian","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","article-title":"Dasatinib: A Potent SRC Inhibitor in Clinical Development for the Treatment of Solid Tumors","volume":"36","author":"Araujo","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1113462","DOI":"10.3389\/fonc.2023.1113462","article-title":"Adverse Reactions after Treatment with Dasatinib in Chronic Myeloid Leukemia: Characteristics, Potential Mechanisms, and Clinical Management Strategies","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Oncol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/leu.2016.188","article-title":"Principal Component Analysis Uncovers Cytomegalovirus-Associated NK Cell Activation in Ph+ Leukemia Patients Treated with Dasatinib","volume":"31","author":"Ishiyama","year":"2017","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving Outcomes in Chronic Myeloid Leukemia through Harnessing the Immunological Landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"879124","DOI":"10.3389\/fimmu.2022.879124","article-title":"Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control","volume":"13","author":"Bernard","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_10","first-page":"2064","article-title":"Role of NKG2D and Its Ligands in Cancer Immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1080\/10428194.2022.2090549","article-title":"The Prognostic Role of NKG2A Expression for Patients with Chronic Myeloid Leukemia after Treatment Discontinuation","volume":"63","author":"Xu","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/25785826.2020.1796062","article-title":"Allelic Polymorphisms of KIRs and Antitumor Immunity against Chronic Myeloid Leukemia","volume":"44","author":"Shindo","year":"2021","journal-title":"Immunol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of Natural Killer Cells by Host Major Histocompatibility Complex Class I Molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.it.2017.12.001","article-title":"Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned","volume":"39","author":"Boudreau","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-09-245746","article-title":"Education of Human Natural Killer Cells by Activating Killer Cell Immunoglobulin-like Receptors","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.4049\/jimmunol.166.5.2992","article-title":"Different NK Cell Surface Phenotypes Defined by the DX9 Antibody Are Due to KIR3DL1 Gene Polymorphism","volume":"166","author":"Gardiner","year":"2001","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4049\/immunohorizons.2100054","article-title":"KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia","volume":"5","author":"Izumi","year":"2021","journal-title":"Immunohorizons"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.4049\/jimmunol.160.10.4951","article-title":"HLA-E Surface Expression Depends on Binding of TAP-Dependent Peptides Derived from Certain HLA Class I Signal Sequences","volume":"160","author":"Lee","year":"1998","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eaag1672","DOI":"10.1126\/sciimmunol.aag1672","article-title":"Class I HLA Haplotypes Form Two Schools That Educate NK Cells in Different Ways","volume":"1","author":"Horowitz","year":"2016","journal-title":"Sci. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbmt.2017.10.039","article-title":"Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study","volume":"24","author":"Costantini","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3389\/fimmu.2018.02433","article-title":"Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function","volume":"9","author":"Damele","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1021\/cb500116c","article-title":"Evaluating the Promiscuous Nature of Tyrosine Kinase Inhibitors Assessed in A431 Epidermoid Carcinoma Cells by Both Chemical- and Phosphoproteomics","volume":"9","author":"Giansanti","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML Patients with Deep Molecular Responses to TKI Have Restored Immune Effectors and Decreased PD-1 and Immune Suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JBM.S187005","article-title":"Assessment of Soluble Cytotoxic T Lymphocyte-Associated Antigen-4, Transforming Growth Factor \u03921, and Platelet-Derived Microparticles during Dasatinib Therapy for Patients with Chronic Myelogenous Leukemia","volume":"10","author":"Nomura","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","article-title":"Regulatory T Cell Inhibition by Dasatinib Is Associated with Natural Killer Cell Differentiation and a Favorable Molecular Response\u2014The Final Results of the D-First Study","volume":"66","author":"Najima","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","article-title":"The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses","volume":"14","author":"Christiansson","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal Expansion of T\/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/cbt.27310","article-title":"Large Granular Lymphocytosis during Dasatinib Therapy","volume":"15","author":"Qiu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-018-2517-0","article-title":"Dasatinib-Induced Anti-Leukemia Cellular Immunity through a Novel Subset of CD57 Positive Helper\/Cytotoxic CD4 T Cells in Chronic Myelogenous Leukemia Patients","volume":"108","author":"Watanabe","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/Oligoclonal T and NK Cells Are Common in Chronic Myeloid Leukemia Patients at Diagnosis and Expand during Dasatinib Therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid Mobilization of Cytotoxic Lymphocytes Induced by Dasatinib Therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after Treatment with Dasatinib in Chronic Myeloid Leukemia: Effects on Response and Toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural Killer or Natural Killer\/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1038\/s41598-017-18062-x","article-title":"Divergent Roles for Antigenic Drive in the Aetiology of Primary versus Dasatinib-Associated CD8+ TCR-V\u03b2+ Expansions","volume":"8","author":"Lissina","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1038\/s41598-020-60195-z","article-title":"Innate T-A\u03b2 Lymphocytes as New Immunological Components of Anti-Tumoral \u201coff-Target\u201d Effects of the Tyrosine Kinase Inhibitor Dasatinib","volume":"10","author":"Barbarin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different Immunoprofiles in Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-Cell Immunoglobulin-like Receptor Gene Profile Predicts Good Molecular Response to Dasatinib Therapy in Chronic Myeloid Leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exp. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E916","DOI":"10.1002\/ijc.27537","article-title":"Enhancement of Natural Killer Cell Effector Functions against Selected Lymphoma and Leukemia Cell Lines by Dasatinib","volume":"131","author":"Hassold","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_41","first-page":"1762","article-title":"Effects of Dasatinib on the Expansion, Subsets, Receptor Expression and Cytotoxic Function of NK Cells in Vitro","volume":"28","author":"Sheng","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia","volume":"9","author":"Chang","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of Highly Differentiated CD8+ T-Cells or NK-Cells in Patients Treated with Dasatinib Is Associated with Cytomegalovirus Reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.it.2016.01.005","article-title":"Immune Adaptation to Environmental Influence: The Case of NK Cells and HCMV","volume":"37","author":"Brodin","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"93297","DOI":"10.18632\/oncotarget.21377","article-title":"Cytomegalovirus Pulls Strings behind NK Cells","volume":"8","author":"Kadowaki","year":"2017","journal-title":"Oncotarget"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3389\/fphar.2019.01232","article-title":"Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection","volume":"10","author":"Climent","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cas.14692","article-title":"Programmed Cell Death 1-Expressing CD56-Negative Natural Killer (NK) Cell Expansion Is a Hallmark of Chronic NK Cell Activation during Dasatinib Treatment","volume":"112","author":"Ishiyama","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ni.2614","article-title":"Resident Viruses and Their Interactions with the Immune System","volume":"14","author":"Duerkop","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The Concept of Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"30","author":"Richter","year":"2016","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-Free Remission with First- and Second-Generation Tyrosine Kinase Inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-019-0496-8","article-title":"Treatment-Free Remission in CML: The US Perspective","volume":"14","author":"Atallah","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukaemia Who Have Maintained Deep Molecular Response for Longer than 1 Year (DADI Trial): A Multicentre Phase 2 Trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cas.12216","article-title":"Sustained Upregulation of Effector Natural Killer Cells in Chronic Myeloid Leukemia after Discontinuation of Imatinib","volume":"104","author":"Mizoguchi","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural Killer-Cell Counts Are Associated with Molecular Relapse-Free Survival after Imatinib Discontinuation in Chronic Myeloid Leukemia: The IMMUNOSTIM Study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/16078454.2022.2135857","article-title":"Higher Neutrophil Counts Are Associated with Successful Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia","volume":"27","author":"Ureshino","year":"2022","journal-title":"Hematology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased Proportion of Mature NK Cells Is Associated with Successful Imatinib Discontinuation in Chronic Myeloid Leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12185-017-2294-1","article-title":"NKG2D Gene Polymorphisms Are Associated with Disease Control of Chronic Myeloid Leukemia by Dasatinib","volume":"106","author":"Hara","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V128.22.1122.1122","article-title":"Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon Alpha 2 Maintenance Therapy May Enable High Rates of Treatment Discontinuation in Chronic Myeloid Leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Puzzolo, M.C., Breccia, M., Mariglia, P., Colafigli, G., Pepe, S., Scalzulli, E., Mariggi\u00f2, E., Latagliata, R., Guarini, A., and Fo\u00e0, R. (2022). Immunomodulatory Effects of IFN\u03b1 on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195594"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia: Interim Analysis of the STOP 2G-TKI Study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-Year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-Line Treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood.V128.22.1916.1916","article-title":"Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study","volume":"128","author":"Yoshida","year":"2016","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000481945","article-title":"Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group","volume":"94","author":"Takaku","year":"2018","journal-title":"Oncology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.15858","article-title":"Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia Is Associated with an Increased Frequency of Innate CD8(+) T-Cells","volume":"186","author":"Cayssials","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Vig\u00f3n, L., Luna, A., Gal\u00e1n, M., Rodr\u00edguez-Mora, S., Fuertes, D., Mateos, E., Piris-Villaespesa, M., Bautista, G., San Jos\u00e9, E., and Rivera-Torres, J. (2020). Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010042"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful Treatment-Free Remission in Chronic Myeloid Leukaemia and Its Association with Reduced Immune Suppressors and Increased Natural Killer Cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11912-022-01228-w","article-title":"Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Review of the Biological Factors Associated with Treatment-Free Remission","volume":"24","author":"Stuckey","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function","volume":"42","author":"Schlums","year":"2015","journal-title":"Immunity"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/cmi.2016.26","article-title":"NK Cell Education via Nonclassical MHC and Non-MHC Ligands","volume":"14","author":"He","year":"2017","journal-title":"Cell Mol. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"dev200361","DOI":"10.1242\/dev.200361","article-title":"Natural Killer Cells Act as an Extrinsic Barrier for in Vivo Reprogramming","volume":"149","author":"Melendez","year":"2022","journal-title":"Development"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20051884","article-title":"Roles for HLA and KIR Polymorphisms in Natural Killer Cell Repertoire Selection and Modulation of Effector Function","volume":"203","author":"Yawata","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4049\/jimmunol.178.1.235","article-title":"Functional Polymorphism of the KIR3DL1\/S1 Receptor on Human NK Cells","volume":"178","author":"Guinan","year":"2007","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer Immunoglobulin-like Receptors Can Predict TKI Treatment-Free Remission in Chronic Myeloid Leukemia Patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","article-title":"Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML","volume":"6","author":"Ureshino","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for Killer Immunoglobin-like Receptor Haplotype A Predicts Complete Molecular Response to Treatment with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients","volume":"41","author":"Caocci","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B Genotype Predicts Outcomes in CML Patients Treated with Response-Directed Sequential Imatinib\/Nilotinib Strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1535-7163.MCT-20-0336","article-title":"HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1073\/pnas.071548198","article-title":"Control of HIV-1 Viremia and Protection from AIDS Are Associated with HLA-Bw4 Homozygosity","volume":"98","author":"Yunis","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00018-018-2863-3","article-title":"Inhibition of SRC Family Kinases Facilitates Anti-CTLA4 Immunotherapy in Head and Neck Squamous Cell Carcinoma","volume":"75","author":"Yu","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"eaav2437","DOI":"10.1126\/sciadv.aav2437","article-title":"Targeting DDR2 Enhances Tumor Response to Anti-PD-1 Immunotherapy","volume":"5","author":"Tu","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The Tyrosine Kinase Inhibitor Dasatinib Acts as a Pharmacologic on\/off Switch for CAR T Cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib Enhances Anti-Leukemia Efficacy of Chimeric Antigen Receptor T Cells by Inhibiting Cell Differentiation and Exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41577-021-00649-1","article-title":"Engaging Innate Immunity in HIV-1 Cure Strategies","volume":"22","author":"Board","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.tim.2015.11.003","article-title":"Reversal of Latency as Part of a Cure for HIV-1","volume":"24","author":"Rasmussen","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14740338.2017.1313224","article-title":"Tyrosine Kinase Inhibitors: Potential Use and Safety Considerations in HIV-1 Infection","volume":"16","author":"Coiras","year":"2017","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcp.2016.02.002","article-title":"Dasatinib Inhibits HIV-1 Replication through the Interference of SAMHD1 Phosphorylation in CD4+ T Cells","volume":"106","author":"Bermejo","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.celrep.2016.02.022","article-title":"IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle","volume":"14","author":"Coiras","year":"2016","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bcp.2018.08.031","article-title":"Evaluation of Resistance to HIV-1 Infection Ex Vivo of PBMCs Isolated from Patients with Chronic Myeloid Leukemia Treated with Different Tyrosine Kinase Inhibitors","volume":"156","author":"Bermejo","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_91","first-page":"1053","article-title":"Dasatinib: Effects on the Macrophage Phospho Proteome with a Focus on SAMHD1 and HIV-1 Infection","volume":"8","author":"Williams","year":"2022","journal-title":"Clin. Res. HIV AIDS"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAI.0000000000002144","article-title":"Targeting ABL1 or ARG Tyrosine Kinases to Restrict HIV-1 Infection in Primary CD4+ T-Cells or in Humanized NSG Mice","volume":"82","author":"McCarthy","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"114203","DOI":"10.1016\/j.bcp.2020.114203","article-title":"Cytotoxic Cell Populations Developed during Treatment with Tyrosine Kinase Inhibitors Protect Autologous CD4+ T Cells from HIV-1 Infection","volume":"182","author":"Luna","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"114666","DOI":"10.1016\/j.bcp.2021.114666","article-title":"Provirus Reactivation Is Impaired in HIV-1 Infected Individuals on Treatment with Dasatinib and Antiretroviral Therapy","volume":"192","author":"Torres","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114816","DOI":"10.1016\/j.bcp.2021.114816","article-title":"Pharmacologic Control of Homeostatic and Antigen-Driven Proliferation to Target HIV-1 Persistence","volume":"194","author":"Innis","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(22)00302-2","article-title":"Immunological and Virological Findings in a Patient with Exceptional Post-Treatment Control: A Case Report","volume":"10","author":"Climent","year":"2023","journal-title":"Lancet HIV"},{"key":"ref_97","unstructured":"S\u00e1nchez-Gaona, N., Gallego, A., Astorga, A., Rall\u00f3n, N., Benito, J.M., Falc\u00f3, V., Genesc\u00e0, M., and Buz\u00f3n, M.J. (2022, January 12\u201316). Characterization of NK Cells in Elite Controllers Losig HIV Control. [CROI Abstract 307]. Proceedings of the CROI 2022 Conference on Retroviruses and Opportunistic Infections, Virtual."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1038\/cti.2017.22","article-title":"NKG2C+ Memory-like NK Cells Contribute to the Control of HIV Viremia during Primary Infection: Optiprim-ANRS 147","volume":"6","author":"Granjeaud","year":"2017","journal-title":"Clin. Transl. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3389\/fimmu.2018.02290","article-title":"NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies","volume":"9","author":"Hernandez","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fimmu.2018.00474","article-title":"Adaptive Reconfiguration of Natural Killer Cells in HIV-1 Infection","volume":"9","author":"Peppa","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Ciri\u00f3n, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., and Prazuck, T. (2013). Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003211"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/JVI.06728-11","article-title":"Widespread Impact of HLA Restriction on Immune Control and Escape Pathways of HIV-1","volume":"86","author":"Carlson","year":"2012","journal-title":"J. Virol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1128\/CVI.00015-13","article-title":"HLA-B*44 Is Associated with a Lower Viral Set Point and Slow CD4 Decline in a Cohort of Chinese Homosexual Men Acutely Infected with HIV-1","volume":"20","author":"Zhang","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Singh, K.K., Qin, M., Brummel, S.S., Angelidou, K., Trout, R.N., Fenton, T., and Spector, S.A. (2016). Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151364"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1097\/QAD.0000000000002028","article-title":"Inhibitory Natural Killer Cell Receptor KIR3DL1 with Its Ligand Bw4 Constraints HIV-1 Disease among South Indians","volume":"32","author":"Maruthamuthu","year":"2018","journal-title":"AIDS"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aam8825","article-title":"Elevated HLA-A Expression Impairs HIV Control through Inhibition of NKG2A-Expressing Cells","volume":"359","author":"Ramsuran","year":"2018","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.4049\/jimmunol.0902621","article-title":"HIV Protective KIR3DL1 and HLA-B Genotypes Influence NK Cell Function Following Stimulation with HLA-Devoid Cells","volume":"184","author":"Boulet","year":"2010","journal-title":"J. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1086\/655966","article-title":"Mind the Gap: Lack of Association between KIR3DL1*004\/HLA-Bw4-Induced Natural Killer Cell Function and Protection from HIV Infection","volume":"202","author":"Parsons","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1128\/JVI.02652-10","article-title":"Receptor-Ligand Requirements for Increased NK Cell Polyfunctional Potential in Slow Progressors Infected with HIV-1 Coexpressing KIR3DL1*h\/*y and HLA-B*57","volume":"85","author":"Kamya","year":"2011","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nm0396-338","article-title":"Endocytosis of Major Histocompatibility Complex Class I Molecules Is Induced by the HIV-1 Nef Protein","volume":"2","author":"Schwartz","year":"1996","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(00)80065-5","article-title":"The Selective Downregulation of Class I Major Histocompatibility Complex Proteins by HIV-1 Protects HIV-Infected Cells from NK Cells","volume":"10","author":"Cohen","year":"1999","journal-title":"Immunity"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1182\/blood-2004-02-0696","article-title":"Killing of Human Immunodeficiency Virus-Infected Primary T-Cell Blasts by Autologous Natural Killer Cells Is Dependent on the Ability of the Virus to Alter the Expression of Major Histocompatibility Complex Class I Molecules","volume":"104","author":"Bonaparte","year":"2004","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.chom.2016.04.005","article-title":"HIV-1 Vpu Mediates HLA-C Downregulation","volume":"19","author":"Apps","year":"2016","journal-title":"Cell Host Microbe"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Song, R., Lisovsky, I., Lebouch\u00e9, B., Routy, J.-P., Bruneau, J., and Bernard, N.F. (2014). HIV Protective KIR3DL1\/S1-HLA-B Genotypes Influence NK Cell-Mediated Inhibition of HIV Replication in Autologous CD4 Targets. PLoS Pathog, 10.","DOI":"10.1371\/journal.ppat.1003867"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e01185-19","DOI":"10.1128\/JVI.01185-19","article-title":"The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells","volume":"93","author":"Kiani","year":"2019","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chom.2017.06.008","article-title":"HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells","volume":"22","author":"Simoneau","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Vieira, V.A., Adland, E., Malone, D.F.G., Martin, M.P., Groll, A., Ansari, M.A., Garcia-Guerrero, M.C., Puertas, M.C., Muenchhoff, M., and Guash, C.F. (2021). An HLA-I Signature Favouring KIR-Educated Natural Killer Cells Mediates Immune Control of HIV in Children and Contrasts with the HLA-B-Restricted CD8+ T-Cell-Mediated Immune Control in Adults. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1010090"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1089\/aid.2011.0253","article-title":"NKG2C Deletion Is a Risk Factor of HIV Infection","volume":"28","author":"Thomas","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_120","unstructured":"Essat, A., Scott-Algara, D., Monceaux, V., Avettand-Fenoel, V., Didier, C., Caillat-Zucman, S., Orr, S., Theodorou, I., Goujard, C., and Boufassa, F. (2018, January 23\u201327). Association between Immunogenetic Factors and Post-Treatment Control of HIV-1 Infection. ANRS VISCONTI and PRIMO Studies. Proceedings of the 22nd International AIDS Conference (AIDS 2018), Amsterdam, Netherlands."},{"key":"ref_121","unstructured":"S\u00e1ez-Ciri\u00f3n, A. (2019, January 21). Mechanisms of Post-Treatment HIV Control: ANRS VISCONTI Study. Proceedings of the IAS 2019, 10th International Conference on HIV Science, Mexico City, Mexico."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcimb.2020.00233","article-title":"What Can Gamma Delta T Cells Contribute to an HIV Cure?","volume":"10","author":"Juno","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/433188","article-title":"SEROCO-HEMOCO Study Group HIV Controllers: A Homogeneous Group of HIV-1-Infected Patients with Spontaneous Control of Viral Replication","volume":"41","author":"Lambotte","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1093\/hmg\/dds226","article-title":"Fine-Mapping Classical HLA Variation Associated with Durable Host Control of HIV-1 Infection in African Americans","volume":"21","author":"McLaren","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1182\/blood-2011-10-381996","article-title":"Comprehensive Analysis of Unique Cases with Extraordinary Control over HIV Replication","volume":"119","author":"Mendoza","year":"2012","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41598-020-58696-y","article-title":"Permanent Control of HIV-1 Pathogenesis in Exceptional Elite Controllers: A Model of Spontaneous Cure","volume":"10","author":"Casado","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","article-title":"Distinct Viral Reservoirs in Individuals with Spontaneous Control of HIV-1","volume":"585","author":"Jiang","year":"2020","journal-title":"Nature"},{"key":"ref_128","unstructured":"Martinez-Picado, J. (August, January 29). Exceptional HIV Elite Controllers. Towards an HIV Cure. Proceedings of the AIDS 2022 Congress, Montreal, Canada, 28 July 2022; Abstract Supplement Abstracts from AIDS 2022\u2014the 24th International AIDS Conference, Virtual."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/L21-0297","article-title":"A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation","volume":"175","author":"Turk","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, Cellular Senescence, and Cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.devcel.2014.11.012","article-title":"An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA","volume":"31","author":"Demaria","year":"2014","journal-title":"Dev. Cell"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1101\/gad.290635.116","article-title":"The Senescence-Associated Secretory Phenotype Induces Cellular Plasticity and Tissue Regeneration","volume":"31","author":"Ritschka","year":"2017","journal-title":"Genes Dev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"109334","DOI":"10.1016\/j.celrep.2021.109334","article-title":"Targeting Senescent Cells Improves Functional Recovery after Spinal Cord Injury","volume":"36","author":"Martins","year":"2021","journal-title":"Cell Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1152\/physrev.00020.2018","article-title":"Cellular Senescence: Aging, Cancer, and Injury","volume":"99","author":"Calcinotto","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA Damage Pathway Regulates Innate Immune System Ligands of the NKG2D Receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","article-title":"Senescence of Activated Stellate Cells Limits Liver Fibrosis","volume":"134","author":"Krizhanovsky","year":"2008","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"328","DOI":"10.18632\/aging.100897","article-title":"NKG2D Ligands Mediate Immunosurveillance of Senescent Cells","volume":"8","author":"Sagiv","year":"2016","journal-title":"Aging"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.medj.2021.04.014","article-title":"Invariant Natural Killer T Cells Coordinate Removal of Senescent Cells","volume":"2","author":"Arora","year":"2021","journal-title":"Med"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1474-9726.2012.00839.x","article-title":"Reduced Release and Binding of Perforin at the Immunological Synapse Underlies the Age-Related Decline in Natural Killer Cell Cytotoxicity","volume":"11","author":"Hazeldine","year":"2012","journal-title":"Aging Cell"},{"key":"ref_140","first-page":"101380","article-title":"Autologous NK Cells Propagated and Activated Ex Vivo Decrease Senescence Markers in Human PBMCs","volume":"32","author":"Chelyapov","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and Tumour Clearance Is Triggered by P53 Restoration in Murine Liver Carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1101\/sqb.2013.78.020255","article-title":"Immune Surveillance of Unhealthy Cells by Natural Killer Cells","volume":"78","author":"Iannello","year":"2013","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aas9090","article-title":"NK Cell-Mediated Cytotoxicity Contributes to Tumor Control by a Cytostatic Drug Combination","volume":"362","author":"Ruscetti","year":"2018","journal-title":"Science"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3892\/ijmm.2022.5095","article-title":"Doxorubicin Sensitizes Breast Cancer Cells to Natural Killer Cells in Connection with Increased Fas Receptors","volume":"49","author":"Sawasdee","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1038\/s41467-019-10335-5","article-title":"Senescent Cells Evade Immune Clearance via HLA-E-Mediated NK and CD8+ T Cell Inhibition","volume":"10","author":"Pereira","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"eabg1703","DOI":"10.1126\/sciimmunol.abg1703","article-title":"HLA-E-Restricted, Gag-Specific CD8+ T Cells Can Suppress HIV-1 Infection, Offering Vaccine Opportunities","volume":"6","author":"Yang","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nature13638","article-title":"Tumour-Infiltrating Gr-1+ Myeloid Cells Antagonize Senescence in Cancer","volume":"515","author":"Toso","year":"2014","journal-title":"Nature"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2016.09.003","article-title":"Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression","volume":"30","author":"Eggert","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","article-title":"The Achilles\u2019 Heel of Senescent Cells: From Transcriptome to Senolytic Drugs","volume":"14","author":"Zhu","year":"2015","journal-title":"Aging Cell"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"14532","DOI":"10.1038\/ncomms14532","article-title":"Cellular Senescence Mediates Fibrotic Pulmonary Disease","volume":"8","author":"Schafer","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_151","first-page":"e21229","article-title":"Senolytic Therapy Ameliorates Renal Fibrosis Postacute Kidney Injury by Alleviating Renal Senescence","volume":"35","author":"Li","year":"2021","journal-title":"FASEB J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cmet.2019.05.006","article-title":"Acceleration of \u03b2 Cell Aging Determines Diabetes and Senolysis Improves Disease Outcomes","volume":"30","author":"Andle","year":"2019","journal-title":"Cell Metab."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/acel.12458","article-title":"Chronic Senolytic Treatment Alleviates Established Vasomotor Dysfunction in Aged or Atherosclerotic Mice","volume":"15","author":"Roos","year":"2016","journal-title":"Aging Cell"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/gerona\/glab002","article-title":"Senolytic Combination of Dasatinib and Quercetin Alleviates Intestinal Senescence and Inflammation and Modulates the Gut Microbiome in Aged Mice","volume":"76","author":"Saccon","year":"2021","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Silva, D., Cant\u00f3n-Sandoval, J., Mart\u00ednez-Navarro, F.J., P\u00e9rez-S\u00e1nchez, H., de Oliveira, S., Mulero, V., Alcaraz-P\u00e9rez, F., and Cayuela, M.L. (2022). Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models of Chronic Inflammation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810468"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in Idiopathic Pulmonary Fibrosis: Results from a First-in-Human, Open-Label, Pilot Study","volume":"40","author":"Justice","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics Decrease Senescent Cells in Humans: Preliminary Report from a Clinical Trial of Dasatinib plus Quercetin in Individuals with Diabetic Kidney Disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41591-022-01923-y","article-title":"Cellular Senescence and Senolytics: The Path to the Clinic","volume":"28","author":"Chaib","year":"2022","journal-title":"Nat. Med."},{"key":"ref_159","unstructured":"Climent, N., Casanova, V., Maleno, M.J., Rodr\u00edguez-Agust\u00edn, A., S\u00e1nche-Palomino, S., Gonz\u00e1lez, T., Hurtado, C., Mart\u00ednez, E., Mallolas, J., and Ambrosioni, J. (2022, January 12\u201316). HIV-Induced Cellular Senescence in PLWH Is Decreased by D+Q Senolytic Drugs. [CROI Abstract 223]. Proceedings of the CROI 2022 Conference on Retroviruses and Opportunistic Infections, Virtual."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cell.2017.02.031","article-title":"Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging","volume":"169","author":"Baar","year":"2017","journal-title":"Cell"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fonc.2018.00459","article-title":"Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer","volume":"8","author":"Kovacovicova","year":"2018","journal-title":"Front. Oncol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/917\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:52:51Z","timestamp":1760122371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":161,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["pharmaceutics15030917"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15030917","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]}}}